TuHURA Biosciences (HURA) to Release Quarterly Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

TuHURA Biosciences Stock Down 12.9 %

Shares of NASDAQ:HURA opened at $2.90 on Tuesday. TuHURA Biosciences has a 52-week low of $2.84 and a 52-week high of $14.60. The stock has a fifty day moving average of $4.35.

Wall Street Analyst Weigh In

Several analysts have issued reports on HURA shares. Maxim Group started coverage on shares of TuHURA Biosciences in a research report on Tuesday, November 5th. They set a “buy” rating and a $15.00 price target for the company. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Finally, RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th.

Institutional Trading of TuHURA Biosciences

An institutional investor recently bought a new position in TuHURA Biosciences stock. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences (NASDAQ:HURA) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 14,314 shares of the company’s stock, valued at approximately $59,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.